NCT03046862View on ClinicalTrials.gov

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 25, 2017

Primary Completion Date

May 30, 2020

Study Completion Date

December 31, 2024

Conditions
Biliary Tract Neoplasms
Interventions
DRUG

Durvalumab

Durvalumab 1.12 g iv on D1 every 3 weeks

DRUG

Tremelimumab

Tremelimumab 75mg iv on D1 every 3 weeks

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks

DRUG

Cisplatin

Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER